PEA 600 mg for Opioid Use Disorder (OUD)

Phase-Based Progress Estimates
Brigham and Women's Hospital, Boston, MA
Opioid Use Disorder (OUD)+1 More
Palmitoylethanolamide - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will investigate whether the dietary supplement palmitoylethanolamide (PEA) can help reduce craving and prevent relapse in patients with opioid use disorder. PEA 600 mg is used to treat Opioid Use Disorder (OUD) and is provided free of charge.

Eligible Conditions

  • Opioid Use Disorder (OUD)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Opioid Use Disorder (OUD)

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: day 21

day 21
stress-induced opioid craving

Trial Safety

Safety Progress

1 of 3

Other trials for Opioid Use Disorder (OUD)

Trial Design

2 Treatment Groups

PEA 600 mg
1 of 2
1 of 2
Active Control
Non-Treatment Group

16 Total Participants · 2 Treatment Groups

Primary Treatment: PEA 600 mg · Has Placebo Group · Phase < 1

PEA 600 mg
ActiveComparator Group · 1 Intervention: Palmitoylethanolamide · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: day 21
Closest Location: Brigham and Women's Hospital · Boston, MA
Photo of Boston 1Photo of Boston 2Photo of Boston 3
2008First Recorded Clinical Trial
5 TrialsResearching Opioid Use Disorder (OUD)
1056 CompletedClinical Trials

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,454 Previous Clinical Trials
9,700,864 Total Patients Enrolled
5 Trials studying Opioid Use Disorder (OUD)
311 Patients Enrolled for Opioid Use Disorder (OUD)

Eligibility Criteria

Age 18+ · All Participants · 8 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a diagnosis of OUD.
You are fluent in English.\n
You are agreeable to abstaining from using any cannabis or CBD-containing products for the duration of the trial.
Use hormonal methods such as birth control pills, patches, injections, vaginal rings, or implants.
Use a barrier method with a spermicide.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.